GlassScriptPhysician profile
David C Osafo
NPI 1467489542
$11,316.84
in general payments reported to CMS, 2019-2025
57 companies · $2,063 in 2025
The $2,063 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $931 · 2021: $857 · 2022: $1,698 · 2023: $2,651 · 2024: $2,241 · 2025: $2,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,496 · Education: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,495.94 |
| Education | $458.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,140.09 | 2019-2025 | |
| Janssen Biotech, INC. | $1,064.32 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $905.34 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $746.30 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Amgen INC. | $598.54 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Exelixis INC. | $505.42 | 2019-2025 | Cabometyx |
| Celgene Corporation | $479.90 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $441.30 | 2020-2025 | Xtandi, Xospata, Vyloy |
| Daiichi Sankyo INC. | $409.01 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $354.70 | 2019-2025 | |
| Eisai INC. | $278.85 | 2020-2025 | |
| Incyte Corporation | $263.41 | 2019-2025 | Monjuvi, Jakafi |
| Genentech USA, INC. | $251.33 | 2022-2025 | Tecentriq, Polivy, Phesgo |
| Beigene USA, INC. | $243.77 | 2020-2024 | Brukinsa |
| Genzyme Corporation | $241.38 | 2021-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $241.00 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $236.01 | 2020-2024 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $219.93 | 2019-2025 | Iclusig, Ninlaro, Alunbrig |
| Sanofi-Aventis U.S. LLC | $191.99 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $158.42 | 2019-2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $156.07 | 2020-2025 | |
| Sobi, INC | $132.42 | 2022-2025 | |
| Gilead Sciences, INC. | $129.67 | 2019-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $125.90 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Lilly USA, LLC | $122.94 | 2020-2025 | Jaypirca, Verzenio |
| Stemline Therapeutics INC. | $110.69 | 2023-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $105.28 | 2019-2025 | Ultomiris |
| Dova Pharmaceuticals | $104.94 | 2021 | |
| Glaxosmithkline, LLC. | $104.77 | 2023-2025 | Ojjaara, Blenrep |
| Global Blood Therapeutics, INC. | $101.65 | 2020-2022 | |
| Puma Biotechnology, INC. | $98.00 | 2019-2025 | |
| Taiho Oncology, INC. | $95.39 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $91.72 | 2023-2024 | Ingrezza, Ongentys |
| Karyopharm Therapeutics INC. | $89.64 | 2020-2021 | |
| Tesaro, INC. | $69.69 | 2019 | |
| Mirati Therapeutics, INC. | $68.61 | 2023-2024 | Krazati |
| Array Biopharma INC | $61.67 | 2023-2025 | Braftovi, Tukysa, Mektovi |
| Blueprint Medicines Corporation | $58.17 | 2022-2024 | Ayvakit |
| Adc Therapeutics America, INC. | $55.55 | 2022-2024 | |
| Beone Medicines USA, INC. | $54.87 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $43.13 | 2022 | |
| Abbvie INC. | $38.66 | 2025 | |
| Emd Serono, INC. | $33.27 | 2022-2025 | |
| Blue Earth Diagnostics | $33.06 | 2020-2022 | |
| Organon LLC | $24.71 | 2022 | |
| Sk Life Science, INC. | $24.47 | 2022 | |
| Progenics Pharmaceuticals, INC. | $23.62 | 2023 | Pylarify |
| Pharmaand Gmbh | $23.42 | 2025 | Rubraca |
| Pharmaessentia USA Corporation | $22.91 | 2023 | Besremi |
| Adaptive Biotechnologies Corporation | $21.73 | 2024 | Clonoseq |
| Tolmar, INC. | $20.86 | 2025 | Rubraca, Eligard |
| Acadia Pharmaceuticals INC | $18.95 | 2024 | Nuplazid |
| Neurelis, INC. | $18.78 | 2023 | Valtoco |
| Alnylam Pharmaceuticals INC. | $17.35 | 2020 | |
| Secura Bio, INC. | $16.29 | 2024 | Copiktra |
| Pharmacosmos Therapeutics INC. | $14.00 | 2023 | Monoferric |
| Seagen INC. | $12.98 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Osafo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.